Phase 1/2 Study of a Candidate CMV Vaccine in Healthy Adults

Phase 2, randomised, double-blind trial of pentamer/gB/adjuvant vaccine in cytomegalovirus infection (CMV) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration, Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration and 6 more. Started Oct 2021; status: completed.